ERBB2 and neoplasm: If such changes in HER2 status will affect post-neoadjuvant treatment decisions, such as the tailoring of subsequent adjuvant therapy, based on these results, we suggest that HER2 should be re-tested in post-neoadjuvant surgical specimens, particularly in HER2 2+/HER2 amplified tumours.